You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝康醫療-B(02170.HK)上半年營收同比增長24.6%,擬構建輔助生殖領域完整產業鏈
格隆匯 08-31 00:01

格隆匯8月30日丨貝康醫療-B(02170.HK)公佈中期業績,截至2023年6月30日止六個月,收入增加24.6%至人民幣8550萬元。該增加主要由於PGT試劑盒銷售的穩步增長與超低温儲存設備的銷售增長所致。毛利增加11.3%至人民幣3360萬元。研發開支增加40.0%至人民幣6370萬元,主要由於產品研發進度的提升使得研發團隊員工成本及臨牀試驗開支增加。

公吿稱,為實現公司願景,公司擬實施以下業務戰略:(i)構建輔助生殖領域完整產業鏈,打造儀器設備、試劑、培養液等耗材的完整產品組合,向輔助生殖機構銷售全球頂尖的產品,服務臨牀產業;(ii)基於PGT產品在銷售渠道上形成的客户積累,以及本地化實驗室的佈局,公司將嫁接現有資源在現有客户中實現其他優勢產品銷售;(iii)建立廣泛全球銷售網絡以擴展國際市場,促進公司自主開發產品進入新市場;及(iv)公司將通過公司總部的建設打造覆蓋輔助生殖全產業鏈產品的高端製造集羣,實現高品質的交付能力,堅持自主研發和國產替代的產業化發展,為國內患者提供符合全球質量標準並且價格更低的試劑、儀器、設備及耗材。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account